Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gluteq
- Development stage
- Unknown
- Lead developer
- Percos India
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Peptides
- Administration
- Oral, Sublingual
01
Overview
Gluteq is an oral liquid and intra-oral spray formulation marketed as a dietary supplement for skin brightening, lightening, and managing hyperpigmentation, melasma, and facial melanosis. Developed by Percos India, the formulation contains a combination of reduced L-glutathione, vitamin C (L-ascorbic acid), cranberry extract, and alfalfa extract. It acts as an antioxidant to neutralize free radicals, reduce oxidative stress, and inhibit melanin production by targeting tyrosinase, thereby improving skin tone and elasticity.
- Brand names
- Gluteq
- Other names
- Gluteq Intra-Oral SprayGluteq Oral LiquidGluteq Oral Spray
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on Gluteq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gluteq.